MINIREVIEWS

68  Fifteen years of bone marrow mononuclear cell therapy in acute myocardial infarction

Micheu MM, Dorobantu M
World Journal of Stem Cells (WJSC, online ISSN 1948-0210, DOI: 10.4252), is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJSC covers topics concerning all aspects of stem cells: embryonic, neural, hematopoietic, mesenchymal, tissue-specific, and cancer stem cells; the stem cell niche, stem cell genomics and proteomics, and stem cell techniques and their application in clinical trials.

We encourage authors to submit their manuscripts to WJSC. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

World Journal of Stem Cells is now indexed in PubMed, PubMed Central, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Biological Abstracts, and BIOSIS Previews.

I-V

Editorial Board

NAME OF JOURNAL
World Journal of Stem Cells

ISSN
ISSN 1948-0210 (online)

LAUNCH DATE
December 31, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Tong Cao, BM BCh, DDS, PhD, Associate Professor, Department of Oral Sciences, National University of Singapore, Singapore 119083, Singapore
Oscar Kuang-Sheng Lee, MD, PhD, Professor, Medical Research and Education of Veterans General Hospital-Taipei, No. 322, Sec. 2, Shih-pai Road, Shih-pai, Taipei 11217, Taiwan

EDITORIAL BOARD MEMBERS
All editorial board members resources online at http://www.wjgnet.com/1948-0210/editorialboard.htm

EDITORIAL OFFICE
Xiu-Xia Song, Director
World Journal of Stem Cells
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com

PUBLICATION DATE
April 26, 2017

COPYRIGHT © 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
http://www.wjgnet.com/bpg/guidlin0204

ONLINE SUBMISSION
http://www.f6publishing.com
Fifteen years of bone marrow mononuclear cell therapy in acute myocardial infarction

Miruna Mihaela Micheu, Maria Dorobantu

Miruna Mihaela Micheu, Maria Dorobantu, Department of Cardiology, Clinical Emergency Hospital of Bucharest, 014461 Bucharest, Romania

Author contributions: Both authors equally contributed to the conception of the paper, the literature review and analysis, drafting and to critically revising and editing the manuscript.

Conflict-of-interest statement: Authors declare no conflict of interests for this article. No financial support.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Correspondence to: Miruna Mihaela Micheu, MD, PhD, Department of Cardiology, Clinical Emergency Hospital of Bucharest, Floreasca Street 8, 014461 Bucharest, Romania. mirunamicheu@yahoo.com

Telephone: +40-72-2451755

Received: January 6, 2017
Peer-review started: January 10, 2017
First decision: February 17, 2017
Revised: March 16, 2017
Accepted: April 18, 2017
Article in press: April 19, 2017
Published online: April 26, 2017

Abstract

In spite of modern treatment, acute myocardial infarction (AMI) still carries significant morbidity and mortality worldwide. Even though standard of care therapy im-proves symptoms and also long-term prognosis of patients with AMI, it does not solve the critical issue, specifically the permanent damage of cardiomyocytes. As a result, a complex process occurs, namely cardiac remodeling, which leads to alterations in cardiac size, shape and function. This is what has driven the quest for unconventional therapeutic strategies aiming to regenerate the injured cardiac and vascular tissue. One of the latest breakthroughs in this regard is stem cell (SC) therapy. Based on favorable data obtained in experimental studies, therapeutic effectiveness of this innovative therapy has been investigated in clinical settings. Of various cell types used in the clinic, autologous bone marrow derived SCs were the first used to treat an AMI patient, 15 years ago. Since then, we have witnessed an increasing body of data as regards this cutting-edge therapy. Although feasibility and safety of SC transplant have been clearly proved, its efficacy is still under dispute. Conducted studies and meta-analysis reported conflicting results, but there is hope for conclusive answer to be provided by the largest ongoing trial designed to demonstrate whether this treatment saves lives. In the meantime, strategies to enhance the SCs regenerative potential have been applied and/or suggested, position papers and recommendations have been published. But what have we learned so far and how can we properly use the knowledge gained? This review will analytically discuss each of the above topics, summarizing the current state of knowledge in the field.

Key words: Bone marrow stem cells; Acute myocardial infarction; Cell therapy; Cardiac regeneration; Remodeling

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Since the first successful bone marrow stem cells transplantation performed 15 years ago in a patient with acute myocardial infarction, we have witnessed a mounting body of data as regards this cutting-edge therapy. During the reporting period, conflicting results have been stated, scientific papers have been under investigation, strategies...
to enhance the stem cells regenerative potential have been applied and/or suggested, position papers and recommendations have been published. This review will analytically discuss each of the above topics, summarizing the current state of knowledge in the field.

Micheu MM, Dorobantu M. Fifteen years of bone marrow mononuclear cell therapy in acute myocardial infarction. World J Stem Cells 2017; 9(4): 68-76. Available from: URL: http://www.wjgnet.com/1948-0210/full/v9/i4/68.htm DOI: http://dx.doi.org/10.4252/wjsc.v9.i4.68

INTRODUCTION

The optimal management of acute myocardial infarction (AMI) still remains elusive, although it represents an illness with one of the highest morbi-mortality and one of the highest healthcare costs worldwide. The quick and efficient restoring of myocardial blood flow is the most appropriate strategy for reducing the size of the infarcted area. Even though standard-of-care therapy diminishes the area at risk to become necrotic, cardiac remodeling may occur in up to 60% of patients having suffered an AMI[1-3]. The conventionalavailable treatments (whether pharmacological, interventional or surgical)[4] do not address the crucial issue of cell loss, thus being unable to completely prevent or reverse this pathological process which eventually leads to changes in size, shape, structure and function of the entire heart. One of the latest breakthroughs in this regard is stem cell (SC) therapy. By providing a potential source of new cells, heart function may be enhanced. Ideally, this process allows the replacement of non-functional cardiomyocytes and scar tissue with new fully functional contracting cells, as well as new blood vessels. Furthermore, transplanted SCs may secrete a variety of growth factors and cytokines, thereby enhancing myocyte survival and facilitating the migration of remote and/or resident cardiac SCs to the site of injury.

One of the first SC types which have been tested in clinical settings is autologous bone marrow SC. Since the first successful bone marrow SCs transplantation performed 15 years ago in a 46-year-old patient with AMI, we have witnessed a mounting body of data related to this effervescent domain: Conflicting results have been reported, scientific papers have been under investigation, strategies to enhance the SCs regenerative potential have been applied and/or suggested, position papers and recommendations have been published. A time line chart of accomplishments performed during the last fifteen years is depicted in Figure 1. But what have we learned so far and how can we properly use the knowledge gained? This review will analytically discuss each of the above topics, summarizing the current state of knowledge in the field.

HALLMARK CLINICAL TRIALS

Bone marrow is a very heterogeneous compartment with multiple SC populations with putative cardiac regenerative potential (e.g., hematopoietic SCs, mesenchymal SCs, endothelial progenitor cells, etc.).

The regenerative potential of adult autologous SCs after AMI was assessed for the first time in 2001 by a German group[5]. They used unfractionated bone marrow mononuclear stem cells (BMMNCs), which contained both hematopoietic and nonhematopoietic cells, a protocol that was extensively used subsequently. After selective catheterization of the infarct-related artery, the BMMNCs suspension has been intracoronary injected. Ten weeks later, the infarct area had been notably reduced (from 24.6% to 15.7%); in addition, cardiac function had improved by 20%-30%. Accordingly, the authors concluded that intracoronary administration of human autologous adult BMMNCs is feasibly in clinical settings and that it can promote myocardial regeneration after transmural infarction.

The following years were characterized by a series of small Phase I clinical trials whose primary achievement was demonstrating the feasibility and safety of this ground-breaking therapy[6-10].

Since most of these studies have been comprehensively discussed in previous reviews[11-14], we will briefly point out their main characteristics. What they have in common is the small number of patients enrolled (with or without a control group) and the assessment of left ventricular ejection fraction (LVEF) as a surrogate marker of cardiac function. Although not designed to evaluate the efficacy of the therapy, the early trials reported a beneficial effect on cardiac function as revealed by increased global or regional LVEF, reduced endystolic LV volumes and enhanced perfusion within the infarcted area 4 to 6 mo after SC transplantation depending on study design.

The next logical step was the appearance of randomized clinical trials (RCT) designed to test whether this therapy works. A wide variety of RCT have been conducted in this regard, with number of patients ranging from 2[15,16] to 204[17], but not all studies successfully blinding the participants and/or caregivers[15,16]. Studies varied also in terms of baseline LVEF, as well as diagnostic tests and procedures used to evaluate cardiac volumes and function. The most utilized imagistic method was cardiac echocardiography followed by cardiac magnetic resonance (CMR) - the “gold” standard for noninvasively characterizing cardiac function and viability, while LV angiography and single-photon emission computed tomography (SPECT) being exploited less frequently. Noteworthy, the timing of cell delivery after AMI, the quantity and quality of transplanted cells, as well as cell handling varied greatly, so is no wonder why apparently similar studies had different results.

Some of the hallmark studies using unfractionated bone marrow mononuclear SCs were conducted more
than 10 years ago (Table 1). The BOOST study tested the usefulness of autologous BMMNCs intracoronary transfer 4.8 ± 1.3 d after AMI[10]. At baseline (n = 60), the two groups of patients were homogeneous in terms of LV volumes and function; 6 mo later, a mean global LVEF improvement of 6.7% in the cell therapy group and 0.7% in the control group (P value for between-group comparison = 0.0026) was documented, enhanced LV systolic function being predominantly witnessed in myocardial segments bordering the infarcted area.

Although significant augmentation of LV function after SCs transplant have been observed in the first months, this positive effect seems to be fading in time. Long-term benefit of SC therapy was assessed in BOOST surviving patients. Eighteen months after AMI (n = 59), there were no significant differences between groups as regards global LVEF (P = 0.27), although the speed to LVEF recovery was significantly higher in patients receiving SC transplant (P = 0.001)[18].

Moreover, 5 years after randomization (n = 56), statistical analysis of data revealed no difference between groups with reference to cardiac dimensions or function. Repetitive CMR examinations indicated an evident dilatation of LV volumes, whereas LV function decreased during 61 mo follow-up[19].

Reinfusion of enriched progenitor cells and infarct remodeling in acute myocardial infarction (REPAIR-AMI) - the largest study reported so far, also demonstrated the benefit of BMMNCs intracoronary infusion in patients with optimally treated AMI. From the 204 patients included, 103 were randomly assigned to placebo group and 101 to receive SC therapy. Both groups were well matched with respect to baseline characteristics, procedural characteristics of reperfusion therapy and associated pharmacological therapy during the study. Three to 7 d after successful stent implantation, cell suspension or placebo medium was injected in the infarct-related artery. Four months later, significant improvement in both global and regional LV function was documented in the cell treated group. Of note, the study led by Andreas Zeiher was the first trial to evaluate the interaction between the BMMNCs treatment effect and the timing of cell delivery. Subgroup analysis revealed superior recovery of contractile function when cell infusion was administered on day 5 or later after PCI, while earlier administration - within 4 d after reperfusion therapy - had only minimal effects as regards LVEF improvement. Furthermore, intracoronary administration of BMC abolished LV end-systolic volume enlargement after the infarction.

Even though REPAIR-AMI was not powered to detect significant differences in major adverse clinical events between the cell therapy and control group, a reduction in the combined outcome of death, recurrence of MI, or any revascularization procedure was noticed[17].

As opposed to BOOST trial - in which positive effects have faded in time, 2- and 5-year follow-up of REPAIR-AMI patients demonstrated a persistent reduction of the combined end point of death, recurrent MI and rehospitalization for heart failure in the BMMNCs group compared with placebo. In addition, 2 years after AMI, SC therapy was still associated with a significant improvement in regional left ventricular contractility of infarcted segments[20,21].

The significant and longstanding positive effects of SC therapy were further confirmed by a study conducted by Bodo-Eckehard Strauer’s group: The BALANCE Study (Clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with AMI) which randomized 124 patients to BMMNCs (62 patients) or control (62 patients) 7 ± 2 d after AMI[22]. The patients were followed-up at specific time intervals (i.e., 3, 12, and 60 mo) by a variety of examinations (e.g., coronary angiography, right heart catheterization, biaxial left ventriculography, electrocardiogram at rest and exercise, echocardiography, late potential, heart rate variability and 24-h Holter electrocardiogram). The authors reported significant improvements as regards LV performance, quality of life and mortality in their 5-year data.

But there were also some studies (not few) that challenged these optimistic findings. In some cases, contradictory results of similar studies were revealed...
on functional activity of isolated cells, consequently affecting the clinical outcome. Seeger et al. collected bone marrow from healthy volunteers or patients with angiographically confirmed coronary artery disease. Equal aliquots from the same bone marrow aspirate were manipulated accordingly to either REPAIR-AMI (density gradient centrifugation using Ficoll, followed by overnight incubation in ex-vivo 10 medium + 20% autologous serum at room temperature), or ASTAMI (density gradient centrifugation using Lymphoprep, followed by overnight incubation in 0.9% NaCl + 20% heparin-plasma at 4 °C) protocol. Obtained BMMNCs were subsequently tested for various parameters of phenotype and function, with quite divergent results. REPAIR-AMI isolation protocol generated a superior number of total BMMNCs, but also more haematopoietic and mesenchymal SCs as compared to ASTAMI. Furthermore, cells isolated and stored according to German study yielded better results in terms of proliferative capacity, ability to migrate to the chemoattractant SDF-1 and improvement in blood flow in a mouse model of hind-limb ischaemia.

Moreover, there is a substantial individual variability related to quantitative but also qualitative changes of adult bone marrow SCs with age, cardiovascular risk factors and associated comorbidities, decreasing the efficiency of cell therapy particularly in patients who need it the most. Studies have shown that young age and a superior number of CD34+ cells were independent predictors for treatment response to cell therapy, demonstrating the importance of patient’s cell product. Additionally, the natural history of AMI has an unpredictable course modulated by upregulation and downregulation of a wide array of cytokines, growth and inflammatory factors. In specific subgroups of patients this changeable biological milieu could blur and/or make it difficult to distinguish a cell-based specific efficacy signal.

Some other potentially incriminated factors associated to result variability could be related to different times simultaneously to the scientific community; this is the case of two well-known studies - REPAIR-AMI and ASTAMI respectively, which were published in the same issue of The New England Journal of Medicine in 2006 [17,23]. As opposed to REPAIR-AMI, the trial conducted by the Norwegian group reported no changes in LVEF, LV volumes or infarct size assessed at 6 mo by SPECT, echocardiography and CMR in 97 patients treated with intracoronary BMMNCs vs placebo a median of 6 d post AMI.

The pile of negative findings expanded based on the results of 3 other studies - namely SWISS-AMI [24], TIME [25] and Late TIME [26] - thoroughly analyzed by Simari and colleagues in a paper on behalf of Cardiovascular Cell Therapy Research Network [27]. The Cardiovascular Cell Therapy Research Network (CCTRN) was intended to enable cell based therapies in the United States [28]; in this regard, CCTRN sponsored the TIME and LateTIME trials which aimed to evaluate the influence of BMMNCs delivery timing on LV function. The 3 studies mentioned above shared some similar characteristics, but differed in some other aspects. All were prospective, randomized, controlled trials designed to identify moderate to large placebo-adjusted LVEF improvements from 3.5% to 5% as assessed by CMR 4 or 6 mo after PCI. Cell dose and delivery were the same in each of the 3 studies - that was the intracoronary stop-flow technique described in the early 2000s [27], but cell handling varied: It was manual Ficoll processing in SWISS-AMI, while the investigators of the CCTRN studies went for automated Ficoll processing. The authors reported no benefit of intracoronary administration of BMMNCs related to LV function irrespective of the timing of delivery. But why apparently similar studies led to contradictory results? These conflicting outcomes have been debated - and to some extent explained - by a series of experts in the field [17,20,30].

A direct comparative analysis of methodology used in REPAIR-AMI [17] and ASTAMI [23] trials have revealed that seemingly minor changes in BMMNCs isolation and preservation protocols may have a major impact

| Study name | Clinical trials (gov ID) | Principal investigator | No. of included patients |
|------------|-------------------------|------------------------|--------------------------|
| BOOST [19,29,30] | NCT00264316 | Stefan Janssens | Treated (n = 30) |
| REPAIR-AMI [17,23] | NCT00279175 | Andreas Zeiher | Treated (n = 101) |
| ASTAMI [24] | NCT00199823 | Ketil Lunde | Treated (n = 50) |
| BALANCE [25] | - | Bodo-Eckehard Strauer | Treated (n = 62) |
| SWISS-AMI [24] | NCT00355186 | Roberto Corti | Treated (n = 133) |
| TIME [25] | NCT0064021 | Robert Simari | Treated (n = 79) |
| Late TIME [26] | NCT0064060 | Robert Simari | Treated (n = 57) |

The results of 3 other studies - namely SWISS-AMI, TIME and ASTAMI respectively, which were published in the same issue of The New England Journal of Medicine in 2006 [17,23,25]. As opposed to REPAIR-AMI, the trial conducted by the Norwegian group reported no changes in LVEF, LV volumes or infarct size assessed at 6 mo by SPECT, echocardiography and CMR in 97 patients treated with intracoronary BMMNCs vs placebo a median of 6 d post AMI.

The pile of negative findings expanded based on the results of 3 other studies - namely SWISS-AMI [24], TIME [25] and Late TIME [26] - thoroughly analyzed by Simari and colleagues in a paper on behalf of Cardiovascular Cell Therapy Research Network [27]. The Cardiovascular Cell Therapy Research Network (CCTRN) was intended to enable cell based therapies in the United States [28]; in this regard, CCTRN sponsored the TIME and LateTIME trials which aimed to evaluate the influence of BMMNCs delivery timing on LV function. The 3 studies mentioned above shared some similar characteristics, but differed in some other aspects. All were prospective, randomized, controlled trials designed to identify moderate to large placebo-adjusted LVEF improvements from 3.5% to 5% as assessed by CMR 4 or 6 mo after PCI. Cell dose and delivery were the same in each of the 3 studies - that was the intracoronary stop-flow technique described in the early 2000s [27], but cell handling varied: It was manual Ficoll processing in SWISS-AMI, while the investigators of the CCTRN studies went for automated Ficoll processing. The authors reported no benefit of intracoronary administration of BMMNCs related to LV function irrespective of the timing of delivery. But why apparently similar studies led to contradictory results? These conflicting outcomes have been debated - and to some extent explained - by a series of experts in the field [17,20,30].

A direct comparative analysis of methodology used in REPAIR-AMI [17] and ASTAMI [23] trials have revealed that seemingly minor changes in BMMNCs isolation and preservation protocols may have a major impact...
between AMI and SCs delivery or to variability methods for the assessment of ventricular function and perfusion (ventriculography, echo-cardiography, CMR, SPECT).

META-ANALYSIS

Because of low sample size and small effects, individual studies were underpowered to identify significant differences in major adverse clinical events between SC therapy and control group. Therefore, new approaches were needed. In hope of obtaining clear answers regarding the effectiveness of SC therapy, several meta-analysis were carried-out since 2006, but the controversies continued\textsuperscript{[13,36,38–52]}. Extensive or less-extensive analysis were performed based on different parameters such as baseline LVEF, timing of SCs infusion from onset of AMI, the dose of BMMNCs infused and patients age. Although earlier meta-analysis reported that intracoronary BMMNCs infusion is associated with significant improvements of LV function and remodeling particularly in younger patients and patients with a more severely depressed LVEF at baseline\textsuperscript{[13,36,45]}, recent analysis revealed that intracoronary cell therapy provided only modest\textsuperscript{[53,54]}, or no benefit in terms of clinical events or changes in LV function\textsuperscript{[52]}. But then, why such discrepancy even between meta-analysis reports? This was the theme of 2 very recent reviews published by well-known experts in the field\textsuperscript{[55,56]}. As one would expect, the first variation factor to point the finger to is related to differences in the methodology used in conducting systematic reviews. All meta-analyses except the one reporting negative findings relied on published summary results from multiple trials, while the latter was based on individual patient data (IPD) collected directly from the researchers responsible for each study and further centrally re-analyzed. The 2 methodologies varied in data collection, data checking and data analysis. Although ACCRUE (Meta-Analysis of Cell-Based Cardiac Studies; NCT01098591) database comprised a pool of 1252 IPDs from 12 randomized studies in AMI settings, it included only about 60% of the available published trials, as a result raising concern for potential bias. Of course, there are some other disparity factors involved, such as insufficient power of included studies, patients’ heterogeneity and statistical heterogeneity\textsuperscript{[55,56]}

In view of presented data, one can only state that meta-analyses failed as well to clarify whether or not SC therapy improves heart function and/or mortality in AMI patients. What is more, meta-analyses are not surrogates for large phase III RCTs. Consequently, the scientific community is eagerly waiting for the ongoing BAMI trial to provide a more conclusive answer as regards the efficacy of bone marrow cell therapy in AMI settings. BAMI (the Effect of Intracoronary Reinfusion of Bone Marrow-Derived Mononuclear Cells on All Cause Mortality in AMI; NCT01569178) is the largest and most aspiring trial to date, funded by the European Commission Seventh Framework Programme. It currently involves 19 partners planning to include 3000 patients from 10 European countries. The study aims to standardize methods of bone marrow cell collection, handling and delivery, as well as to test if the product and delivery method can lead to a 25% reduction in mortality.

PRESENT AND FUTURE STRATEGIES

TO IMPROVE BONE MARROW SCs

REGENERATIVE POTENTIAL

Since BMMNCs yielded only modest improvements regarding LV function recovery after AMI, selected bone marrow SCs populations have been tested in clinical settings. Trials involving CD34\textsuperscript{+}/CD133\textsuperscript{+} progenitor cells\textsuperscript{[37–61]} or mesenchymal stem cells (MSCs)\textsuperscript{[62–65]} had encouraging results, but none of these tested cells haven’t been clearly demonstrated to yield superior outcomes.

Of course, strategies to increase the number and potency of low-abundance progenitor cells in bone marrow cells (e.g., MSCs, CD34\textsuperscript{+}/CD133\textsuperscript{+} cells) are needed. While in animal models a variety of genetic and nongenetic approaches aiming to improve therapeutic efficacy of transplanted cells have been tested, there is still a long road till translation into clinical settings. Some of the genetic strategies include enhancement of survival, proliferation and differentiation capacity, as well as boost of paracrine factors synthesis. Nongenetic procedures in essence comprise preconditioning with various factors (physical factors, drugs, cytokines and growth factors), 3D aggregate formation or hydrogel encapsulation and coculture with other types of SCs (e.g., cardiac SCs)\textsuperscript{[66,67]}

In addition, unlike in chronic ischemic disease, strategies to improve bone marrow SCs regenerative potential in acute settings are limited by the relatively short window of opportunity.

DRAWBACKS

Most important drawbacks and limitations of BMMNCs in AMI settings are related to reduced regenerative potential of transplanted cells; therefore, finding strategies to intensify their survival, proliferation and differentiation potential is a perpetual quest. But aside from these methodological features discussed in previous chapter, we would like to bring your attention to another issue, namely scientific inaccuracy. Unfortunately, SC research has not been avoided by scandals related to “scientific misconduct” in the field. It is the case of studies conducted by the German scientist Bodo-Eckehard Strauer. His papers have been comprehensively analyzed by Francis et al\textsuperscript{[68]} who identified and exposed a series of discrepancies and contradictions such as number of patients receiving cells, baseline EF comparability and cell preparation. Although none of Strauer’s studies have been retracted, their results cannot be trusted any more. Nevertheless, we chose to include them in our review in order to provide the reader
with an accurate depiction of SC therapy development in AMI settings, since the German investigator conducted not only the pioneering research in this area, but also one of the largest and most promising trials in the field. Besides affecting the credibility of the researchers, these inconsistencies may negatively influence the patients’ decision when considering enrollment in a SC-based clinical trial.

REFERENCES

The European Society of Cardiology Working Group Cellular Biology of the Heart has recently provided a series of recommendations on how to improve the therapeutic application of cell-based therapies for cardiac regeneration and repair[22]. Accordingly, upcoming studies should be designed to address precise hypotheses on delivery types and mechanisms of efficiency, rather than safety and efficacy endpoints only; comparison of different cell types, or a combination of cell types in RCTs should be completed; in-depth cell characterization - including cell function should be done in every clinical trial; also, strategies to boost both cellular and paracrine effects should be developed.

CONCLUSION

A substantial knowledge has been gained in the past 15 years since the first bone marrow SCs transplantation have been performed in a patient with AMI, but there are a lot of challenges to be faced until this therapy will gain a definitive place in clinical arena.

PERSPECTIVES AND RECOMMENDATIONS

Predicting who will benefit and who will not from SC therapy is not currently possible, although efforts are being made in this direction[27]. In the era of Precision Medicine Initiative[69][70], being able to discriminate responders from nonresponders could be the first step toward tailored cell therapy. Prediction models for responder identification based on individual’s characteristics are mandatory, in order that every single patient gets optimal treatment according to his individual variations in genes, environment and lifestyle.

Investigators of future trials should carefully choose hard clinically meaningful end points not limited to one effect, but rather reflecting different categories of consequences, such as structural evaluations of the heart, cardiovascular physiological measurements, biomarkers (including transcriptomic-based biomarkers), functional capacity and quality of life[71].

with an accurate depiction of SC therapy development in AMI settings, since the German investigator conducted not only the pioneering research in this area, but also one of the largest and most promising trials in the field. Besides affecting the credibility of the researchers, these inconsistencies may negatively influence the patients’ decision when considering enrollment in a SC-based clinical trial.

PERSPECTIVES AND RECOMMENDATIONS

Predicting who will benefit and who will not from SC therapy is not currently possible, although efforts are being made in this direction[27]. In the era of Precision Medicine Initiative[69][70], being able to discriminate responders from nonresponders could be the first step toward tailored cell therapy. Prediction models for responder identification based on individual’s characteristics are mandatory, in order that every single patient gets optimal treatment according to his individual variations in genes, environment and lifestyle.

Investigators of future trials should carefully choose hard clinically meaningful end points not limited to one effect, but rather reflecting different categories of consequences, such as structural evaluations of the heart, cardiovascular physiological measurements, biomarkers (including transcriptomic-based biomarkers), functional capacity and quality of life[71].

The European Society of Cardiology Working Group Cellular Biology of the Heart has recently provided a series of recommendations on how to improve the therapeutic application of cell-based therapies for cardiac regeneration and repair[22]. Accordingly, upcoming studies should be designed to address precise hypotheses on delivery types and mechanisms of efficiency, rather than safety and efficacy endpoints only; comparison of different cell types, or a combination of cell types in RCTs should be completed; in-depth cell characterization - including cell function should be done in every clinical trial; also, strategies to boost both cellular and paracrine effects should be developed.

CONCLUSION

A substantial knowledge has been gained in the past 15 years since the first bone marrow SCs transplantation have been performed in a patient with AMI, but there are a lot of challenges to be faced until this therapy will gain a definitive place in clinical arena.

REFERENCES

1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. *Circulation* 1990; 81: 1161-1172 [PMID: 2138525]
2. Pfeffer MA. Left ventricular remodeling after acute myocardial infarction. *Annu Rev Med* 1995; 46: 455-466 [PMID: 7598478 DOI: 10.1146/annurev.med.46.1.455]
3. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. *JACC Cardiovascular Imaging* 2011; 4: 98-108 [PMID: 21232712 DOI: 10.1016/j.jcmg.2010.10.008]
4. Sing PG, James SK, Atar D, Badano LP, Böhmström-Lundqvist C, Borger MA, Di Marco C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knutti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van’t Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2012; 33: 2569-2619 [PMID: 22922416 DOI: 10.1093/eurheartj/ehs215]
5. Time for a new paradigm? Cell-based therapies for treatment of acute myocardial infarction. *J Am Coll Cardiol* 2010; 56: 742-748 [PMID: 20000144798.54040.ed]
6. Abdel-Latif A, Assmann B, Sluzewski M, Rau J, Seifert B, Knappe S, Zeiher AM. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). *Circulation* 2002; 106: 3009-3017 [PMID: 1237544]
7. Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klingle H, Schünchlen C, Nienaber CA, Freund M, Steinhoff G. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. *Lancet* 2003; 361: 45-46 [PMID: 12517467 DOI: 10.1016/S0140-6736(03)12110-1]
8. Fernández-Aviles F, San Román JA, García-Grade F, Fernández ME, Peharnbora MJ, de la Fuente L, Gómez-Bueno M, Cantapielea A, Fernández J, Gutierréz O, Sánchez PL, Hernández C, Sanz R, García-Sancho J, Sánchez A. Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. *Circ Res* 2004; 95: 742-748 [PMID: 15558665 DOI: 10.1161/01.RES. 00000144798.54040.ed]
9. Wollert KC, Meyer GP, Lotz J, Ringle-Leichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Gansser A, Drexler H. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. *Lancet* 2004; 364: 141-148 [PMID: 15246726 DOI: 10.1016/S0140-6736(04)61626-9]
10. Abdel-Latif A, Bolli R, Tleyjeh IM, Monetti VM, Perin EC, Hornung CA, Zaha-Surma EK, Al-Mallah MH, David B. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. *Arch Intern Med* 2007; 167: 989-997 [PMID: 17533201 DOI: 10.1001/archinte.167.10.989]
11. Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. *Arterioscler Thromb Vasc Biol* 2008; 28: 208-216 [PMID: 17951319 DOI: 10.1161/ATVBAHA.107.155317]
12. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. *Eur Heart J* 2008; 29: 1807-1818 [PMID: 18523058 DOI: 10.1093/eurheartj/ehn220]
13. Strauer BE, Steinhoff G. 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: from the methodological origin to clinical practice. *J Am Coll Cardiol* 2011; 58: 1095-1104 [PMID: 21884944 DOI: 10.1016/j.jacc.2011.06.016]
14. Ruan W, Pan CZ, Huang QG, Li YL, Ge JB, Shu XH. Assessment of left ventricular segmental function after autologous bone marrow stem cells transplantation in patients with acute myocardial infarction by tissue tracking and strain imaging. *Chin Med J (Engl)* 2005; 118: 1175-1181 [PMID: 16117862]
15. Gu J, Li Y, Qian J, Shi J, Wang Q, Niu Y, Fan B, Liu X, Zhang S, Sun A, Zou Y. Efficacy of emergent transcatheter transplantation of stem cells for treatment of acute myocardial infarction (TCT-STAMI). *Heart* 2006; 92: 1764-1767 [PMID: 16775089 DOI: 10.1136/heart.2005. 085431]
Bone marrow therapy in myocardial infarction

17 Schächinger V, Erbs S, Elsässer A, Haberbach W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamn CW, Stüsebeck T, Assmus B, Tonn T, Dimmler S, Zeiher AM. Intra coronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355: 1210-1221 [PMID: 16903084 DOI: 10.1056/NEJMoa061866]

18 Meyer GP, Wollert KC, Lotz J, Steffens F, Lippolt P, Fichtner S, Hecker H, Schaefer A, Arseniev L, Hertenstein B, Banser A, Drexl H. Intra coronary bone marrow cell transfer after myocardial infarction: eight months' follow-up from the randomized, controlled BOOST (Bone marrow transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006; 113: 1287-1294 [PMID: 16520413 DOI: 10.1161/CIRCULATIONAHA.105.575118]

19 Meyer GP, Wollert KC, Lotz J, Prr J, Rager U, Lippolt P, Hahn A, Fichtner S, Schaefer A, Arseniev L, Banser A, Drexl H. Intra coronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 2009; 30: 2978-2984 [PMID: 19773226 DOI: 10.1093/eurheartj/elp374]

20 Assmus B, Rolf A, Erbs S, Elsässer A, Haberbach W, Hambrecht R, Tillmanns H, Yu J, Corti R, Mathey DG, Hamn CW, Stüsebeck T, Tonn T, Dimmler S, Tilt D, Zeiher AM, Schächinger V. Clinical outcome 2 years after intra coronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail 2010; 3: 89-96 [PMID: 19996415 DOI: 10.1161/CIRCHEARTFAILURE.108.843243]

21 Assmus B, Leistner DM, Schächinger V, Erbs S, Elsässer A, Haberbach W, Hambrecht R, Seding D, Yu J, Corti R, Mathey DG, Barth C, Mayer-Wehrstein C, Burch I, Stüsebeck T, Tilt D, Hamn CW, Tonn T, Dimmler S, Zeiher AM. Long-term clinical outcome after intra coronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival. Eur Heart J 2014; 35: 1275-1283 [PMID: 24569031 DOI: 10.1093/eurheartj/ehu062]

22 Yousef M, Scharnweil CM, Köstering M, Zeis T, Brehm M, Struver BE. The BALANCE Study: clinical benefit and long-term outcome of autologous bone marrow cell transfer in patients with acute myocardial infarction. J Am Coll Cardiol 2009; 53: 2262-2269 [PMID: 19520249 DOI: 10.1016/j.jacc.2009.02.051]

23 Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ibekeb A, Mangsau A, Fjeld SM, Hjeltnik TH, Haraldsdur G, Grogaard HK, Bjørnerheim R, Brevik K, Månsson R, Wollert KC, Lotz J, Pirr J, Rager U, Lippolt P, Hahn A, Fichtner S, Schaefer A, Arseniev L, Banser A, Drexl H. Intra coronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation myocardial infarction) trial. Eur Heart J 2016; 37: 1564-1568 [PMID: 24812350 DOI: 10.1002/ehj2.13072]

24 Henry TD, Moyé L, Traverse JH, Henry TD, Peplin CJ, Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTR-N). J Cardiovasc Transl Res 2010; 3: 36-36 [PMID: 20445812 DOI: 10.1007/s12266-009-9160-3]

25 Seeger FH, Torn T, Krzozosk N, Zeiher AM, Dimmler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 2007; 28: 766-772 [PMID: 17298974 DOI: 10.1093/eurheartj/ehm509]

26 Henry TD, Moyé L, Traverse JH. Consistently Inconsistent-Bone Marrow Mononuclear Stem Cell Therapy Following Acute Myocardial Infarction: A Decade Later. Circ Res 2016; 119: 404-406 [PMID: 27458193 DOI: 10.1161/CIRCRESAHA.116.309231]

27 Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-E7 [PMID: 11440894]

28 MacEneaney OJ, Kushner EJ, Westby CM, Cech JN, Greiner JJ, Stauffer BL, DeSouza CA. Endothelial progenitor cell function, apoptosis, and telomere length in overweight/obese humans. Obesity (Silver Spring) 2010; 18: 1677-1682 [PMID: 20573362 DOI: 10.1038/oby.2009.494]

29 Drea E, Stankowska K, Kulwas A, Roś D. Endothelial progenitor cells in diabetic foot syndrome. Adv Clin Exp Med 2012; 21: 249-254 [PMID: 23214290]

30 Efimenko AY, Kochegura TN, Akopyan ZA, Parfyonova YV. Autologous Stem Cell Therapy: How Aging and Chronic Diseases Affect Stem and Progenitor Cells. Biores Open Access 2015; 4: 26-38 [PMID: 26300780 DOI: 10.1159/000449092]

31 Micheu M, Oprescu O, Dorobantu M. Quantitative determination of endothelial progenitor cells – a new marker for the occurrence of coronary artery disease? J Cardiol 2001; 35: 156-159 [PMID: 11264651]

32 Delevi R, Hirsch A, Tijssen JG, Schächinger V, Wojakowski W, Roncalli J, Aakhus S, Erbs S, Assmus B, Tendera M, Goekmen Turan R, Corti R, Henry TD, Lerman P, Koudstaal S, Sluijter JP, Wojakowski W, Piek JJ, Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. Eur J Heart J 2014; 35: 989-998 [PMID: 24026778 DOI: 10.1093/eurheartj/ehq372]

33 Zwetsloot PP, Gremmels H, Assmus B, Koudstaal S, Sluijter JP, Zeiher AM, Chumaleu SA. Responder Definition in Clinical Stem Cell Trials in Cardiology: Will the Real Responder Please Stand Up? Circ Res 2010; 106: 511-518 [PMID: 27492842 DOI: 10.1161/CIRCRESAHA.116.308733]

34 Hristov M, Heussen N, Schober A, Weber C. Intra coronary infusion of autologous bone marrow cells and left ventricular function after acute myocardial infarction: a meta-analysis. J Cell Mol Med 2006; 10: 727-733 [PMID: 16989732]

35 Lipinski MJ, Biondi-Zoccai GG, Abbate A, Khaneiy R, Srinivasan J, Bartunek J, Vanderheyden M, Kim HS, Kang HJ, Strauss BA, Vetrovec GW. Impact of intracoronary cell therapy on left ventricular function.
function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. *J Am Coll Cardiol* 2007; 50: 1761-1767 [PMID: 17964040 DOI: 10.1016/j.jacc.2007.09.079]

40 Zhang S, Sun A, Xu D, Yao K, Huang Z, Jin H, Wang K, Zou Y, Ge J. Impact of timing on efficacy and safety of intracoronary autologous bone marrow stem cells transplantation in acute myocardial infarction: a pooled subgroup analysis of randomized controlled trials. *Clin Cardiol* 2009; 32: 458-466 [PMID: 19685520 DOI: 10.1002/clc.20575]

41 Zhang SN, Sun AJ, Ge JB, Yao K, Huang ZY, Wang KQ, Zou YZ. Intracoronary autologous bone marrow stem cells transfer for patients with acute myocardial infarction: a meta-analysis of randomised controlled trials. *Int J Cardiol* 2009; 136: 178-185 [PMID: 18646438 DOI: 10.1016/j.ijcard.2008.04.071]

42 Bai Y, Sun T, Ye P. Age, gender and diabetic status are associated with effects of bone marrow cell therapy on recovery of left ventricular function after acute myocardial infarction: a systematic review and meta-analysis. *Aging Res Rev* 2010; 9: 418-423 [PMID: 20471500 DOI: 10.1016/j.arr.2010.05.001]

43 Kuuswardhani RA, Soegito A. Bone marrow-derived stem cells as an adjunctive treatment for acute myocardial infarction: a systematic review and meta-analysis. *Acta Med Indones* 2011; 43: 168-177 [PMID: 21979282]

44 Takagi H, Umemoto T. Intracoronary stem cell injection improves left ventricular remodeling after acute myocardial infarction: an updated meta-analysis of randomized trials. *Int J Cardiol* 2011; 151: 226-228 [PMID: 21641056 DOI: 10.1016/j.ijcard.2011.05.004]

45 Clifford DM, Fisher SA, Brunskill SJ, Doree C, Mathur A, Watt S, Martin-Rendon E. Stem cell treatment for acute myocardial infarction. *Cochrane Database Syst Rev* 2012; (2): CD006536 [PMID: 22336818 DOI: 10.1002/14651858.CD006536.pub3]

46 Zimmet H, Porapakkham P, Porapakkham P, Sata Y, Haas SJ, Itescu S, Forbes A, Krum H. Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials. *Eur J Heart Fail* 2012; 14: 91-105 [PMID: 22065869 DOI: 10.1093/eurjhf/hfr148]

47 Chen L, Tong JY, Jin H, Ren XM, Jin H, Wang QJ, Ma GS. Long-term effects of bone marrow-derived cells transplantation in patients with acute myocardial infarction: a meta-analysis. *Chin Med J (Engl)* 2013; 126: 353-360 [PMID: 23324289]

48 Jeong H, Yim HW, Cho Y, Park HJ, Jeong S, Kim HB, Hong W, Kim H. The effect of rigorous study design in the research of autologous bone marrow-derived mononuclear cell transfer in patients with acute myocardial infarction. *Stem Cell Res Ther* 2013; 4: 82 [PMID: 23849537 DOI: 10.1186/sc233]

49 de Jong R, Houtgraaf J, Samiei S, Boersma E, Duckers HJ. The effect of rigorous study design in the research of autologous bone marrow stem cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Stem Cells in Acute Myocardial Infarction (REGENET) Trial. *Eur Heart J* 2009; 30: 1313-1321 [PMID: 19208649 DOI: 10.1093/eurheartj/ehp073]

50 Colombo A, Castellani M, Piccaluga E, Pusineri E, Falater S, Longari V, Canzi C, Sacchi E, Rossi E, Rech G, Gerardin P, Viecchi M, Deliliers GL, Rebullia P, Soligo D, Giordano R. Myocardial blood flow and infarct size after CD133+ cell injection in large myocardial infarction with good recanalization and poor reperfusion: results from a randomized controlled trial. *J Am Coll Cardiol* 2011; 58: 2277-2286 [PMID: 21619812 DOI: 10.1161/CIRCULATIONAHA.110.977330]

51 Qiyumi AA, Waller EK, Murrow J, Esteves F, Gali J, Oshinsky J, Lakdas S, Shen S, Vaughan D, Perin E, Willerson J, Kereiakes D, Gersh BJ, Gregory D, Werner A, Moss T, Chan W, Kanani S, Preti R, Pecora AL. CD34+ cell injection after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. *Am Heart J* 2011; 161: 98-105 [PMID: 21712740 DOI: 10.1016/j.ahj.2010.09.025]

52 Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunnhua RZ, Liao LM, Lin S, Sun JP. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. *Am J Cardiol* 2004; 94: 92-95 [PMID: 15219514 DOI: 10.1016/j.amjcard.2004.03.034]

53 Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Garstenblith G, DeMaria AN, Denkeas AE, Gammon RS, Hermiller JB, Reisman MA, Schaefer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. *J Am Coll Cardiol* 2009; 54: 2277-2286 [PMID: 19958962]
Gao LR, Pei XT, Ding QA, Chen Y, Zhang NK, Chen HY, Wang ZG, Wang YF, Zhu ZM, Li TC, Liu HL, Tong ZC, Yang Y, Nan X, Guo F, Shen JL, Shen YH, Zhang JJ, Fei YX, Xu HT, Wang LJ, Tian HT, Liu DQ, Yang Y. A critical challenge: dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction. Int J Cardiol 2013; 168: 3191-3199 [PMID: 23651816 DOI: 10.1016/j.ijcard.2013.04.112]

Lee JW, Lee SH, Youn YJ, Ahn MS, Kim JY, Yoo BS, Yoon J, Kwon W, Hong IS, Lee K, Kwan J, Park KS, Choi D, Jang YS, Hong MK. A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction. J Korean Med Sci 2014; 29: 23-31 [PMID: 24431901 DOI: 10.3346/jkms.2014.29.1.23]

Sart S, Ma T, Li Y. Preconditioning stem cells for in vivo delivery. Biores Open Access 2014; 3: 137-149 [PMID: 25126478 DOI: 10.1089/biores.2014.0012]

Karpov AA, Udalova DV, Pliss MG, Galagudza MM. Can the outcomes of mesenchymal stem cell-based therapy for myocardial infarction be improved? Providing weapons and armour to cells. Cell Prolif 2017; 50 [PMID: 27878916 DOI: 10.1111/cpc.12316]

Francis DP, Mielczwicz M, Zargar D, Cole GD. Autologous bone marrow-derived stem cell therapy in heart disease: discrepancies and contradictions. Int J Cardiol 2013; 168: 3381-3403 [PMID: 23830344 DOI: 10.1016/j.ijcard.2013.04.152]

Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372: 793-795 [PMID: 25635347 DOI: 10.1056/NEJMp1500523]

Jaffe S. Planning for US Precision Medicine Initiative underway. Lancet 2015; 385: 2448-2449 [PMID: 26122056 DOI: 10.1016/S0140-6736(15)61124-2]

Hare JM, Bolli R, Cooke JP, Gordon DJ, Henry TD, Perin EC, March KL, Murphy MP, Pepine CJ, Simari RD, Skarlatos SI, Traverse JH, Willerson JT, Szady AD, Taylor DA, Vojvodic RW, Yang PC, Moyé LA. Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN). Circulation 2013; 127: 1630-1635 [PMID: 23588961 DOI: 10.1161/CIRCULATIONAHA.112.000779]

Madonna R, Van Laake LW, Davidson SM, Engel FB, Hausenloy DJ, Lecour S, Leor J, Perrino C, Schulz R, Ytrehus K, Landmesser U, Mummery CL, Janssens S, Willerson J, Eschenhagen T, Ferdinandy P, Sluijter JP. Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur Heart J 2016; 37: 1789-1798 [PMID: 27055812 DOI: 10.1093/eurheartj/ehw113]
